Eight new anticancer therapeutics have received FDA approval just since December 2014. Among them, Palbociclib (Ibrance) was approved for use in combination with letrozole for treating postmenopausal women with estrogen receptor-positive, HER2-negative, metastatic breast cancer. In a Phase II clinical trial, palbociclib added to letrozole (vs. letrozole alone) almost doubled the median time to disease progression. Palbociclib blocks the function of two specific proteins that play a roll in driving cell multiplication in hormone receptor-positive, HER2-negative breast cancer patients. Palbociclib is the first CDK4/6 inhibitor to be approved by the FDA, a major step forward in prolonging disease remission AND reducing the toxicity of metastatic breast cancer treatment. Read the full American Association of Cancer Research article here.